Brainscope Ahead 200
Overview
The BrainScope Ahead 200 is an FDA-cleared, portable, non-invasive medical device that utilizes artificial intelligence and electroencephalography (EEG) to provide objective assessment of brain electrical activity associated with mild traumatic brain injury (mTBI), including concussions and structural injuries like brain bleeds. It is designed to be used as an adjunct to standard clinical practice, aiding healthcare professionals in the evaluation of patients who are being considered for a head Computed Tomography (CT) scan. The device leverages commercial smartphone hardware (Android operating system) with a custom sensor and disposable electrode headset to record and analyze EEG data, providing rapid insights at the point of care. By offering objective biomarkers, the BrainScope Ahead 200 aims to reduce unnecessary head CT scans, decrease radiation exposure, and improve patient triage and management in urgent care settings.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered EEG analysis for objective brain injury assessment
- Portable, non-invasive device for point-of-care use
- Adjunctive assessment for mild traumatic brain injury (mTBI)
- Aids in identifying structural brain injury (e.g., brain bleeds) and functional injury (e.g., concussion)
- Potential to reduce unnecessary head CT scans and radiation exposure
- Utilizes a disposable electrode headset and mobile device interface (Android smartphone-based)
- Rapid assessment capabilities (intended for use within 24 hours of injury for Ahead 200)
- Provides objective biomarkers derived from EEG data
- Available in two models: M-200 (military) and CV-200 (civilian)
- Integrates cognitive performance assessments (e.g., Military Acute Concussion Evaluation - MACE for M-200)
Use Cases
- Emergency department triage for head injury patients
- Assessment of head-injured patients in urgent care clinics
- Traumatic brain injury (TBI) assessment in military settings
- Aiding in the decision-making process for ordering head CT scans
- Reducing unnecessary radiation exposure for patients with mild head injuries
- Concussion assessment in sports programs (later BrainScope devices expanded this focus)
What Physicians Need to Know
BrainScope Ahead 200 is a valuable adjunctive tool for rapidly assessing mild traumatic brain injury (TBI) and concussion at the point of care, particularly in urgent care and emergency department settings. It can help objectively identify patients who may not require a head CT, thereby reducing unnecessary radiation exposure and improving patient flow. Physicians should integrate its objective EEG-based assessments with their standard clinical evaluations for comprehensive patient management. While the company is exploring broader applications, the Ahead 200's current FDA clearance is specifically for TBI assessment in patients aged 18-80 years with a GCS score of 13-15, within 24 hours of injury.
The BrainScope Ahead 200 leverages commercial Android smartphone technology for its operation. It facilitates integration into clinical workflows by providing immediate results on the device and generating PDF reports that can be uploaded to Electronic Medical Record (EMR) systems. BrainScope's broader platform is capable of developing and applying novel biomarkers to EEG data captured by third-party devices, indicating potential for wider integration beyond its proprietary hardware.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Contact vendor for pricing |
| Deployment | Mobile device interface (Android smartphone-based) and cloud-based analytics platform |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Yes AI-estimated The BrainScope Ahead 200 (models M-200 and CV-200) received FDA clearance on May 15, 2015, under K143643. It is a Class II Brain Injury Adjunctive Interpretive Electroencephalograph Assessment Aid, indicated for use as an adjunct to standard clinical practice to aid in the evaluation of patients (aged 18-80 years) who sustained a closed head injury within 24 hours, clinically present as a mild traumatic brain injury (GCS 13-15), and are being considered for a head CT scan. |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Sports Medicine |
What the Web Says
The BrainScope Ahead 200 is an FDA-cleared, handheld medical device designed to objectively assess mild traumatic brain injury (mTBI), including concussion and the likelihood of a brain bleed, within 24 hours of injury. It utilizes EEG technology and AI-powered algorithms to provide rapid results at the point of care, aiming to reduce unnecessary CT scans and improve patient triage. The device is intended for use as an adjunct to standard clinical practice for patients aged 18-80 with a Glasgow Coma Scale (GCS) score of 13-15. While the Ahead 200 itself received FDA clearance in 2015, BrainScope has continued to develop and refine its technology, with subsequent models and systems also receiving clearance.
Overall: PositiveStrengths
- Reduces unnecessary head CT scans and associated radiation exposure.
- Decreases emergency department length of stay.
- Provides rapid, objective assessment of brain injury at the point of care (under 20 minutes).
- Aids in triage and referral for follow-up concussion care.
- Portable and easy to use in various urgent care settings, including military field use.
- High sensitivity (99%) in identifying intracranial bleeding.
Limitations
- Not a substitute for a CT scan for definitive diagnosis.
- Initial Reddit discussions in 2017 raised concerns about a 48% false positive rate for an earlier model (AHEAD 300), though this may not directly reflect the Ahead 200 or later iterations.
- Some users on G2 for Brainscape (a different product by the same company) noted subscription costs as a barrier, which might be a general concern for Brainscope products.
- Limited to patients aged 18-80 with a GCS of 13-15.
- The major risk of the device is a false negative result, which could delay treatment for a structural brain injury.
Based on reviews from: BrainScope Company, Inc. (Press Releases), The United States Army, Air Force Medical Service, Adventist Health, Reddit (r/science), G2, American College of Emergency Physicians (ACEP), PubMed Central (PMC)
Last updated: 2026-07-17
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Brainscope Ahead 200
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Brainscope Ahead 200.
No videos found. Search YouTube directly
No FAQs available yet for this tool.
